Press

Deep functional measurements of Fragile X Syndrome human neurons reveal multiparametric electrophysiological disease phenotype

A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology

Discovery of novel compounds and target mechanisms using a high throughput, multiparametric phenotypic screen in a human neuronal model of Tuberous Sclerosis

Highly Parallelized, Multicolor Optogenetic Recordings of Cellular Activity for Therapeutic Discovery Applications in Ion Channels and Disease-Associated Excitable Cells

Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models

Probing Synaptic Signaling with Optogenetic Stimulation and Genetically Encoded Calcium Reporters

Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome

Quiver Bioscience Announces Collaboration with the Dup15q Alliance to Advance Antisense Oligonucleotide Therapeutic Program

Quiver Bioscience Announces Publication in Nature Communications Biology Detailing Application of the Quiver Genomic Positioning System (Brain GPS) to Therapeutic Discovery in Fragile X Syndrome using Human Models and Machine Learning Analysis

Q-State Biosciences Announces Receipt of Fourth US National Institutes of Health SBIR Funding Award of 2022

Q-State Biosciences Announces Receipt of Third US National Institutes of Health SBIR Funding Award of 2022

Q-State Biosciences Announces New Peer Reviewed Publication Introducing Its Next Generation Swarm™ Optogenetic Measurement Technology System

Q-State Publishes New Research on ASOs in Ultra-rare Neurodegenerative Disorder

Q-State Biosciences Announces New Therapeutic Programs Targeting Neurodegeneration

Q-State Biosciences to Present Research on ASO Design Technology and Therapeutic Development at Two Upcoming Scientific Conferences

Q-State Biosciences Announces Presentation at the World Orphan Drug Congress

Q-State Biosciences Awarded NIH Grant for the Development of ASO Therapies Targeting Cancer Pain

Q-State Biosciences Announces Pre-Clinical Proof-of-Concept Data for Exon-Skipping ASO Therapeutic in Ultra-Rare Neurological Disorder

Q-State Biosciences Announces Presentation at the Upcoming Antiepileptic Drug & Device Trials XVI Symposium

Q-State Biosciences Achieves Milestone of 50 Million Neurons Measured With its Proprietary Optopatch™ Technology

Q-State Biosciences Presents at the 2021 Neuroimmunology Drug Development Summit

Q-State Biosciences Announces Key Appointments to Its Executive Leadership Team

Q-State Celebrates Rare Disease Day

Q-State Biosciences Announces Achievement of Key Research Milestone with Chamishi Therapeutics

Q-State Biosciences Announces Additions and Appointments to its Board of Directors

Q-State Biosciences Announces the Appointment of Biopharma Veteran Paul Medeiros as President and Chief Executive Officer

Q-State Biosciences Awarded $8 Million in Federal Grant Funding in 2019

The Silverstein Foundation and Q-State Biosciences Launch Chamishi Therapeutics

Genomic Positioning System (GPS): High-resolution, high throughput electrophysiology integrated with AI/ML to map diseases, targets, and drugs for CNS therapeutic discovery

High-throughput profiling of the effects of genetic perturbations on electrophysiology in human neurons

Discovery of optimized therapeutics for CNS disorders using the brain Genomic Positioning System (GPS)

Development of Nav1.7 channel targeting antisense oligonucleotide as a chronic pain therapeutic using an integrated platform based on machine learning and optical electrophysiology